Testicular germ cell tumors represent the most common solid malignancy of young men aged 15–40 years. Histopathologically, testicular germ cell tumors are divided into two major groups: pure seminoma and nonseminoma. The pathogenesis of testicular germ cell tumors remains unknown; however, cryptorchidism is the main risk factor, and molecular studies have shown strong evidence of an association between genetic alterations and testicular germ cell tumors. In cases of suspicion for testicular germ cell tumor, a surgical exploration with orchiectomy is obligatory. After completion of diagnostic procedures, levels of serum tumor markers and the clinical stage based on the International Union Against Cancer tumor-node-metastasis classification should be defined. Patients with early-stage testicular germ cell tumors are treated by individualized risk stratification within a multidisciplinary approach. The individual management (surveillance, chemotherapy or radiotherapy) has to be balanced according to clinical features and the risk of short-term and long-term toxic effects. Treatment for metastatic tumors is based on risk stratification according to International Germ Cell Cancer Collaborative Group classification and is performed with cisplatin-based chemotherapy and residual tumor resection in cases of residual tumor lesion. High-dose chemotherapy represents a curative option for patients with second or subsequent relapses.
In cases with suspicion of testicular tumor, analysis of tumor marker levels and a histological proof, usually obtained by an inguinal orchiectomy, is mandatory
In patients with early-stage testicular germ cell tumors, the overall disease-free survival is nearly 100%, irrespective of therapeutic strategy; surveillance remains an effective means of managing these patients
The therapy of advanced testicular germ cell tumors is based on risk stratification according to clinical features and International Germ Cell Cancer Collaborative Group classification (good, intermediate or poor prognosis)
For patients with features suggestive of a good prognosis, chemotherapy with three cycles of bleomycin, etoposide and cisplatin or four cycles of etoposide and cisplatin are the two optimal treatment regimens
In patients with intermediate or poor prognosis features, an intensification of treatment is necessary through four cycles of cisplatin-based chemotherapy in combination with complete resection of residual masses
Relapsed or refractory disease should be treated either with conventional chemotherapy or with high-dose chemotherapy; late relapsing tumors are usually chemotherapy-resistant, and surgical treatment should be the first choice
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bosl, G. J. & Motzer, R. J. Testicular germ-cell cancer. N. Engl. J. Med. 337, 242–253 (1997).
Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. (eds) WHO Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs Ch. 4, 250–262 (IARC Press, Lyon, 2004).
Ulbright, T. M. & Roth, L. M. Recent developments in the pathology of germ cell tumors. Semin. Diagn. Pathol. 4, 304–319 (1987).
Ulbright, T. M. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod. Pathol. 18 (Suppl. 2), S61–S79 (2005).
Horner, M. J. et al. SEER Cancer Statistics Review, 1975–2006, National Cancer Institute, Bethesda[online], (2009).
McGlynn, K. A. et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97, 63–70 (2003).
Garner, M. J., Turner, M. C., Ghadirian, P. & Krewski, D. Epidemiology of testicular cancer: an overview. Int. J. Cancer 116, 331–339 (2005).
McGlynn, K. A. et al. Persistent organochlorine pesticides and risk of testicular germ cell tumors. J. Natl Cancer Inst. 100, 663–671 (2008).
Korkola, J. E., Houldsworth, J., Bosl, G. J. & Chaganti, R. S. Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. BJU Int. 104, 1334–1338 (2009).
Kanetsky, P. A. et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat. Genet. 41, 811–815 (2009).
Korkola, J. E. et al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J. Clin. Oncol. 27, 5240–5247 (2009).
Krege, S. et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur. Urol. 53, 478–496 (2008).
Dieckmann, K. P. & Loy, V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J. Clin. Oncol. 14, 3126–3132 (1996).
De Santis, M. et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol. 22, 1034–1039 (2004).
Krege, S. et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur. Urol. 53, 497–513 (2008).
Hoei-Hansen, C. E., Rajpert-De Meyts, E., Daugaard, G. & Skakkebaek, N. E. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann. Oncol. 16, 863–868 (2005).
von der Maase, H. et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br. Med. J. (Clin. Res. Ed.) 293, 1398–1401 (1986).
Harland, S. J. et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J. Urol. 160, 1353–1357 (1998).
Bayens, Y. C., Helle, P. A., Van Putten, W. L. & Mali, S. P. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother. Oncol. 25, 97–102 (1992).
Coleman, J. M., Coleman, R. E., Turner, A. R., Radstone, C. R. & Champion, A. E. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin. Oncol. (R. Coll. Radiol.) 10, 237–241 (1998).
Jones, W. G. et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J. Clin. Oncol. 23, 1200–1208 (2005).
Santoni, R. et al. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. BJU Int. 92, 47–52 (2003).
Warde, P. et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J. Clin. Oncol. 13, 2255–2262 (1995).
Fosså, S. D. et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J. Clin. Oncol. 17, 1146 (1999).
Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354–1365 (2005).
Oliver, R. T. et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366, 293–300 (2005).
Chung, P. et al. Surveillance in stage I testicular seminoma—risk of late relapse. Can. J. Urol. 9, 1637–1640 (2002).
Warde, P. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20, 4448–4452 (2002).
Daugaard, G., Petersen, P. M. & Rørth, M. Surveillance in stage I testicular cancer. APMIS 111, 76–83 (2003).
Ramakrishnan, S., Champion, A. E., Dorreen, M. S. & Fox, M. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin. Oncol. (R. Coll. Radiol.) 4, 284–286 (1992).
Albers, P. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J. Clin. Oncol. 21, 1505–1512 (2003).
Cullen, M. H. et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol. 14, 1106–1113 (1996).
Studer, U. E. et al. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur. Urol. 23, 444–449 (1993).
van den Belt-Dusebout, A. W. et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370–4378 (2007).
van den Belt-Dusebout, A. W. et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 24, 467–475 (2006).
Albers, P. et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J. Clin. Oncol. 26, 2966–2972 (2008).
Tandstad, T. et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J. Clin. Oncol. 27, 2122–2128 (2009).
Westermann, D. H. et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J. Urol. 179, 163–166 (2008).
Wood, L. et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can. Urol. Assoc. J. 4, e19–e38 (2010).
Kakiashvili, D. M., Zuniga, A. & Jewett, M. A. High risk NSGCT: case for surveillance. World J. Urol. 27, 441–447 (2009).
Zuniga, A., Kakiashvili, D. & Jewett, M. A. Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int. 104, 1351–1356 (2009).
Classen, J. et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J. Clin. Oncol. 21, 1101–1106 (2003).
Schmidberger, H. et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int. J. Radiat. Oncol. Biol. Phys. 39, 321–326 (1997).
Garcia-del-Muro, X. et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J. Clin. Oncol. 26, 5416–5421 (2008).
Winter, C., Raman, J. D., Sheinfeld, J. & Albers, P. Retroperitoneal lymph node dissection after chemotherapy. BJU Int. 104, 1404–1412 (2009).
Horwich, A. & Stenning, S. Initial chemotherapy for stage II testicular non-seminoma. World J. Urol. 12, 148–150 (1994).
Peckham, M. J. & Hendry, W. F. Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. Br. J. Urol. 57, 763–768 (1985).
Logothetis, C. J. et al. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J. Urol. 134, 1127–1130 (1985).
Feuer, E. J. et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J. Clin. Oncol. 12, 368–377 (1994).
de Wit, R. et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br. J. Cancer 71, 1311–1314 (1995).
Culine, S. et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J. Clin. Oncol. 26, 421–427 (2008).
Smith, T. J. et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24, 3187–3205 (2006).
Cullen, M. et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N. Engl. J. Med. 353, 988–998 (2005).
André, F. et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur. J. Cancer 36, 1389–1394 (2000).
Motzer, R. J. et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Clin. Oncol. 15, 2546–2552 (1997).
Hartmann, J. T., Bamberg, M. & Albers, P. Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin [abstract 1607]. Proc. Am. Soc. Clin. Oncol. 22, 400 (2003).
Doyle, D. M. & Einhorn, L. H. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int. J. Radiat. Oncol. Biol. Phys. 70, 1361–1364 (2008).
Hinz, S. et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J. Urol. 179, 936–940 (2008).
Ehrlich, Y., Brames, M. J., Beck, S. D., Foster, R. S. & Einhorn, L. H. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J. Clin. Oncol. 28, 531–536 (2010).
Kollmannsberger, C. et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J. Clin. Oncol. 28, 537–542 (2010).
Fox, E. P. et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol. 11, 1294–1299 (1993).
Flechon, A., Tavernier, E., Meeus, P., Rivoire, M. & Droz, J.-P. Study of the conformity of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) to standard recommendations in patients with testicular (T) and primary retroperitoneal (PR) non-seminomatous germ-cell tumor (NSGCT): impact on outcome. J. Clin. Oncol. (ASCO Meeting Abstracts) 22 (Suppl. July 15), abstr. 4584 (2004).
Fizazi, K. et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann. Oncol. 19, 259–264 (2008).
Fizazi, K. et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J. Clin. Oncol. 19, 2647–2657 (2001).
Lorch, A. et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J. Clin. Oncol. (ASCO Meeting Abstracts) 28 (Suppl. May 20), abstr. 4513 (2010).
Lorch, A. et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann. Oncol. 21, 820–825 (2010).
Lorch, A. et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J. Clin. Oncol. 25, 2778–2784 (2007).
Oldenburg, J. & Fosså, S. D. Late relapse of nonseminomatous germ cell tumours. BJU Int. 104, 1413–1417 (2009).
Oldenburg, J., Wahlqvist, R. & Fosså, S. D. Late relapse of germ cell tumors. World J. Urol. 27, 493–500 (2009).
Kondagunta, G. V. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549–6555 (2005).
Fosså, S. D., Oldenburg, J. & Dahl, A. A. Short- and long-term morbidity after treatment for testicular cancer. BJU Int. 104, 1418–1422 (2009).
Nuver, J. et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J. Clin. Oncol. 23, 3718–3725 (2005).
Huddart, R. A. et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513–1523 (2003).
Fosså, S. D. et al. Noncancer causes of death in survivors of testicular cancer. J. Natl Cancer Inst. 99, 533–544 (2007).
Carnegie, C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev. Urol. 6 (Suppl. 6), S3–S8 (2004).
Lampe, H., Horwich, A., Norman, A., Nicholls, J. & Dearnaley, D. P. Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol. 15, 239–245 (1997).
Brydøy, M. et al. Paternity following treatment for testicular cancer. J. Natl Cancer Inst. 97, 1580–1588 (2005).
Ernst, D. S. et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can. J. Urol. 12, 2575–2580 (2005).
Feldman, D. R. & Motzer, R. J. Good-risk-advanced germ cell tumors: historical perspective and current standards of care. World J. Urol. 27, 463–470 (2009).
Shayegan, B. et al. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int. 99, 993–997 (2007).
The authors declare no competing financial interests.
About this article
Cite this article
Winter, C., Albers, P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 7, 43–53 (2011). https://doi.org/10.1038/nrendo.2010.196
Asian Journal of Urology (2021)
International braz j urol (2021)
Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men
International Journal of Urology (2021)
Primary pure angiosarcoma of the testis: a vanishingly rare malignancy. Case report and literature review
BMC Urology (2020)
Differential gene expression in cisplatin-resistant and -sensitive testicular germ cell tumor cell lines